## Lexette® (halobetasol propionate) – Expanded indication

- On August 18, 2021, the FDA approved Mayne Pharma's Lexette (halobetasol propionate), for the topical treatment of plaque psoriasis in patients 12 years of age and older.
    - Lexette was previously approved for this indication in patients 18 years of age and older.
- The safety and effectiveness of Lexette in patients 12 to less than 18 years of age is supported by evidence from adequate and well-controlled studies in adults and from one open-label safety study in 24 patients aged 12 to less than 18 years.
- The recommended administration of Lexette for all patients is a thin uniform film to the affected skin twice daily for up to two weeks.
    - Therapy should be discontinued when control is achieved. If no improvement is seen within two weeks, reassessment of the diagnosis may be necessary.
    - Treatment beyond two weeks is not recommended and the total dosage should not exceed 50 grams per week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (HPA) axis.